European journal of pharmacology

Tirzepatide reduces liver fat and inflammation in MASLD partly by blocking immune cell signaling

Updated

Abstract

Tirzepatide improved metabolic dysfunction and liver injury in mice with metabolic dysfunction-associated steatotic liver disease (MASLD) induced by a high-fat, high-fructose diet.

  • Tirzepatide treatment significantly reduced hepatic steatosis and inflammatory responses in the MASLD model.
  • RNA sequencing indicated an enrichment of pathways related to C-type lectin receptors and inflammatory signaling.
  • Tirzepatide decreased the accumulation of macrophages and expression of Dectin-1 in the liver.
  • In vitro, tirzepatide inhibited the activation of inflammatory signaling pathways in macrophages stimulated by palmitic acid.
  • Dectin-1 knockdown in macrophages led to reduced inflammatory responses and diminished the effects of tirzepatide.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free